Skip to content
HowShorted

CAPRICOR THERAPEUTICS, INC. short interest in 2018

In 2018, CAPRICOR THERAPEUTICS, INC.'s disclosed short interest ran from 5.90% of shares outstanding on 12 Jan 2018 to 2.72% on 31 Dec 2018, a change of -3.18 percentage points. The year's high was 6.66% on 15 Feb 2018 and its low 2.72% on 31 Dec 2018, averaging 4.65% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 16.11 days on 30 Nov 2018. Full history: CAPRICOR THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CAPRICOR THERAPEUTICS, INC. in 2018

2018 in figures

Start of year
5.90% (12 Jan 2018)
End of year
2.72% (31 Dec 2018)
Change
-3.18 pp
High
6.66% (15 Feb 2018)
Low
2.72% (31 Dec 2018)
Average
4.65%
Highest days to cover
16.11 (30 Nov 2018)
SEC filings marked
8

Every report in 2018

CAPRICOR THERAPEUTICS, INC. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 20185.90%5.17
31 Jan 20185.68%2.11
15 Feb 20186.66%2.04
28 Feb 20186.23%5.66
15 Mar 20185.90%5.70results (8-K)
29 Mar 20185.64%4.4310-K filed
13 Apr 20185.51%5.38
30 Apr 20185.52%7.63
15 May 20185.30%10.16results (8-K), 10-Q filed
31 May 20184.94%11.30
15 Jun 20184.87%3.61
29 Jun 20184.44%7.66
13 Jul 20184.42%3.38
31 Jul 20184.73%3.96
15 Aug 20184.09%10.02results (8-K), 10-Q filed
31 Aug 20184.00%11.82
14 Sep 20183.85%15.90
28 Sep 20183.83%11.03
15 Oct 20183.68%8.54
31 Oct 20183.63%5.70
15 Nov 20183.42%8.40results (8-K), 10-Q filed
30 Nov 20183.38%16.11
14 Dec 20183.21%4.64
31 Dec 20182.72%3.57

See also: CAPRICOR THERAPEUTICS, INC.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.